Bevacizumab-Induced Hypertension
- 1 June 2011
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 25 (3) , 159-169
Abstract
Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF), has been approved in the US as first- and second-line treatment of colorectal cancer...Keywords
This publication has 56 references indexed in Scilit:
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patientsAnnals of Oncology, 2010
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyJournal of Clinical Oncology, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibClinical and Experimental Medicine, 2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Effect of Regular Phosphodiesterase Type 5 Inhibition in HypertensionHypertension, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- Anticancer drug targets: approaching angiogenesisJournal of Clinical Investigation, 1999